Based on the two opposing hypotheses, patients with active brain metastases from HER2-positive breast cancer in the PERMEATE study cohort A were patients without radiotherapy and cohort B were patients who progressed after radiotherapy. The gene discussed is ERBB2; the disease is breast cancer.